Regulation of PARP1/2 and the tankyrases: emerging parallels.


Journal

The Biochemical journal
ISSN: 1470-8728
Titre abrégé: Biochem J
Pays: England
ID NLM: 2984726R

Informations de publication

Date de publication:
04 Sep 2024
Historique:
received: 10 06 2024
revised: 31 07 2024
accepted: 06 08 2024
medline: 23 8 2024
pubmed: 23 8 2024
entrez: 23 8 2024
Statut: ppublish

Résumé

ADP-ribosylation is a prominent and versatile post-translational modification, which regulates a diverse set of cellular processes. Poly-ADP-ribose (PAR) is synthesised by the poly-ADP-ribosyltransferases PARP1, PARP2, tankyrase (TNKS), and tankyrase 2 (TNKS2), all of which are linked to human disease. PARP1/2 inhibitors have entered the clinic to target cancers with deficiencies in DNA damage repair. Conversely, tankyrase inhibitors have continued to face obstacles on their way to clinical use, largely owing to our limited knowledge of their molecular impacts on tankyrase and effector pathways, and linked concerns around their tolerability. Whilst detailed structure-function studies have revealed a comprehensive picture of PARP1/2 regulation, our mechanistic understanding of the tankyrases lags behind, and thereby our appreciation of the molecular consequences of tankyrase inhibition. Despite large differences in their architecture and cellular contexts, recent structure-function work has revealed striking parallels in the regulatory principles that govern these enzymes. This includes low basal activity, activation by intra- or inter-molecular assembly, negative feedback regulation by auto-PARylation, and allosteric communication. Here we compare these poly-ADP-ribosyltransferases and point towards emerging parallels and open questions, whose pursuit will inform future drug development efforts.

Identifiants

pubmed: 39178157
pii: 234875
doi: 10.1042/BCJ20230230
doi:

Substances chimiques

Tankyrases EC 2.4.2.30
PARP2 protein, human EC 2.4.2.30
Poly (ADP-Ribose) Polymerase-1 EC 2.4.2.30
Poly(ADP-ribose) Polymerases EC 2.4.2.30
PARP1 protein, human EC 2.4.2.30
TNKS2 protein, human EC 2.4.2.30
TNKS protein, human EC 2.4.2.30
Poly(ADP-ribose) Polymerase Inhibitors 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1097-1123

Informations de copyright

© 2024 The Author(s).

Auteurs

Matthew Jessop (M)

Division of Structural Biology, The Institute of Cancer Research (ICR), London, U.K.
Division of Cancer Biology, The Institute of Cancer Research (ICR), London, U.K.

Benjamin J Broadway (BJ)

Division of Structural Biology, The Institute of Cancer Research (ICR), London, U.K.
Division of Cancer Biology, The Institute of Cancer Research (ICR), London, U.K.

Katy Miller (K)

Division of Structural Biology, The Institute of Cancer Research (ICR), London, U.K.
Division of Cancer Biology, The Institute of Cancer Research (ICR), London, U.K.

Sebastian Guettler (S)

Division of Structural Biology, The Institute of Cancer Research (ICR), London, U.K.
Division of Cancer Biology, The Institute of Cancer Research (ICR), London, U.K.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH